Bromodomain-Containing Protein 4: A Druggable Target
Authors:
- 12 November 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 20 (15) , 1517-1536
Abstract
Bromodomain-containing protein 4 (BRD4) belongs to the bromodomain and extraterminal family. BRD4 inhibitors can regulate acetylated lysine and form protein complexes that initiate transcriptional programs as an epigenetic regulator of the histone code. BRD4 was initially considered to be one of the most promising targets for combating malignant tumors. However, many recent studies have shown that BRD4 plays a crucial role in various kinds of diseases, including cancer, coronary heart disease, neurological disorder, and obesity. Currently, several BRD4 inhibitors are undergoing clinical trials. A search for new BRD4 inhibitors appears to be of great utility for developing novel drugs. In this mini-review, we highlight the inhibitors of BRD4 from natural products and synthesized sources, as well as their applications in cancer, glucolipid metabolism, inflammation, neuronal stimulation activation, human immunodeficiency virus and renal fibrosis.Keywords
Funding Information
- National Natural Science Fund (81872763)
- Shanghai Science and Technology Committee (16401902000)
This publication has 116 references indexed in Scilit:
- Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived HitJournal of Medicinal Chemistry, 2012
- Reactivation of Latent HIV-1 by Inhibition of BRD4Cell Reports, 2012
- BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domainProceedings of the National Academy of Sciences, 2012
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences of the United States of America, 2011
- Bromodomains as therapeutic targetsExpert Reviews in Molecular Medicine, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- NUT midline carcinomaCancer Genetics and Cytogenetics, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Resveratrol: A review of preclinical studies for human cancer preventionToxicology and Applied Pharmacology, 2007